Volume | 93,643 |
|
|||||
News | - | ||||||
Day High | 4.77 | Low High |
|||||
Day Low | 4.385 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Eagle Pharmaceuticals Inc | EGRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.69 | 4.385 | 4.77 | 4.69 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,275 | 93,643 | $ 4.52 | $ 423,568 | - | 4.10 - 30.43 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:42:25 | 79 | $ 4.37 | USD |
Eagle Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
57.01M | 12.99M | - | 316.61M | 35.64M | 2.74 | 1.60 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Eagle Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EGRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.88 | 5.26 | 4.28 | 4.90 | 177,748 | -0.49 | -10.04% |
1 Month | 5.51 | 5.82 | 4.28 | 4.96 | 159,101 | -1.12 | -20.33% |
3 Months | 4.75 | 6.81 | 4.28 | 5.46 | 197,369 | -0.36 | -7.58% |
6 Months | 13.55 | 14.78 | 4.10 | 5.97 | 218,880 | -9.16 | -67.60% |
1 Year | 30.01 | 30.43 | 4.10 | 11.63 | 188,327 | -25.62 | -85.37% |
3 Years | 43.97 | 58.25 | 4.10 | 28.26 | 152,750 | -39.58 | -90.02% |
5 Years | 49.80 | 64.94 | 4.10 | 36.93 | 152,555 | -45.41 | -91.18% |
Eagle Pharmaceuticals Description
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration. |